Label: ENBREL- etanercept kit
ENBREL- etanercept solution

  • NDC Code(s): 58406-010-01, 58406-010-04, 58406-010-96, 58406-021-01, view more
  • Packager: Immunex Corporation
  • Category: HUMAN PRESCRIPTION DRUG LABEL
  • DEA Schedule: None
  • Marketing Status: Biologic Licensing Application

Drug Label Information

Updated March 3, 2025

If you are a consumer or patient please visit this version.

  • HIGHLIGHTS OF PRESCRIBING INFORMATION
    These highlights do not include all the information needed to use ENBREL safely and effectively. See full prescribing information for ENBREL. ENBREL® (etanercept) injection, for subcutaneous use ...
  • Table of Contents
    Table of Contents
  • BOXED WARNING (What is this?)
    SERIOUS INFECTIONS - Patients treated with Enbrel are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1) and Adverse ...

    WARNING: SERIOUS INFECTIONS and MALIGNANCIES

    SERIOUS INFECTIONS

    Patients treated with Enbrel are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions (5.1) and Adverse Reactions (6)]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids.

    Enbrel should be discontinued if a patient develops a serious infection or sepsis.

    Reported infections include:

    • Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Test patients for latent tuberculosis before Enbrel use and during therapy. Initiate treatment for latent infection prior to Enbrel use.
    • Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Consider empiric anti-fungal therapy in patients at risk for invasive fungal infections who develop severe systemic illness.
    • Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria.

    The risks and benefits of treatment with Enbrel should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection.

    Monitor patients closely for the development of signs and symptoms of infection during and after treatment with Enbrel, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy.

    MALIGNANCIES

    Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF-blockers, including Enbrel.

    Close
  • 1 INDICATIONS AND USAGE
    1.1 Rheumatoid Arthritis - Enbrel is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function ...
  • 2 DOSAGE AND ADMINISTRATION
    2.1 Testing and Procedures Prior to Treatment Initiation - Perform the following evaluations and procedures prior to initiating treatment with Enbrel: Prior to initiating Enbrel and periodically ...
  • 3 DOSAGE FORMS AND STRENGTHS
    Injection: 25 mg/0.5 mL and 50 mg/mL clear, colorless solution in a single-dose prefilled syringe - Injection: 50 mg/mL clear, colorless solution in a single-dose prefilled SureClick ...
  • 4 CONTRAINDICATIONS
    Enbrel is contraindicated in patients with sepsis.
  • 5 WARNINGS AND PRECAUTIONS
    5.1 Serious Infections - Patients treated with Enbrel are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or ...
  • 6 ADVERSE REACTIONS
    The following serious adverse reactions are discussed in greater detail in other sections of the labeling: Serious Infections [see Warnings and Precautions (5.1)] Neurologic Reactions [see ...
  • 7 DRUG INTERACTIONS
    Specific drug interaction studies have not been conducted with Enbrel. 7.1 Vaccines - Most PsA patients receiving Enbrel were able to mount effective B-cell immune responses to pneumococcal ...
  • 8 USE IN SPECIFIC POPULATIONS
    8.1 Pregnancy - Risk Summary - Available studies with use of etanercept during pregnancy do not reliably support an association between etanercept and major birth defects. Clinical data are ...
  • 10 OVERDOSAGE
    No dose-limiting toxicities have been observed during clinical trials of Enbrel. Single IV doses up to 60 mg/m2 (approximately twice the recommended dose) have been administered to healthy ...
  • 11 DESCRIPTION
    Etanercept, a tumor necrosis factor (TNF) blocker, is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor ...
  • 12 CLINICAL PHARMACOLOGY
    12.1 Mechanism of Action - TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. It plays an important role in the inflammatory processes of RA ...
  • 13 NONCLINICAL TOXICOLOGY
    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility - Long-term animal studies have not been conducted to evaluate the carcinogenic potential of etanercept or its effect on ...
  • 14 CLINICAL STUDIES
    14.1 Adult Rheumatoid Arthritis - The safety and efficacy of Enbrel were assessed in four randomized, double-blind, controlled studies. The results of all four trials were expressed in ...
  • 15 REFERENCES
    National Cancer Institute. Surveillance, Epidemiology, and End Results Database (SEER) Program. SEER Incidence Crude Rates, 13 Registries, 1992-2002. Bröms G, Granath F, Ekbom A, et al. Low ...
  • 16 HOW SUPPLIED/STORAGE AND HANDLING
    Enbrel (etanercept) injection is supplied as a clear and colorless sterile, preservative-free solution for subcutaneous administration in single-dose prefilled syringes, an Enbrel single-dose ...
  • 17 PATIENT COUNSELING INFORMATION
    Advise the patient and/or caregiver to read the FDA-approved patient labeling (Medication Guide and Instructions for Use) before the patient starts using Enbrel, and each time the prescription is ...
  • SPL UNCLASSIFIED SECTION
    AMGEN - Enbrel® (etanercept) Manufactured by: Immunex Corporation - Thousand Oaks, CA 91320-1799 - U.S. License Number 1132 - Patent: http://pat.amgen.com/enbrel/ © 1998-2024 Immunex Corporation ...
  • MEDICATION GUIDE
    This Medication Guide has been approved by the U.S. Food and Drug Administration.Revised: 09/2024 - Medication Guide - Enbrel® (en-brel) (etanercept) injection, for subcutaneous ...
  • INSTRUCTIONS FOR USEENBREL® (en-brel)(etanercept)injection, for subcutaneous use50 mg/mLsingle-dose prefilled SureClick® autoinjector
    This Instructions for Use contains information on how to inject ENBREL with a SureClick autoinjector. If your healthcare provider decides that you or a caregiver may be able to give your ...
  • Instructions for Use Enbrel® (en-brel) (etanercept) injection, for subcutaneous use Single-dose Prefilled Syringe
    How do I prepare and give an injection with Enbrel Single-dose Prefilled Syringe? There are 2 types of Enbrel single-dose prefilled syringes: The 50 mg/mL single-dose prefilled syringe that ...
  • Instructions for UseEnbrel® (en-brel)(etanercept)for injection, for subcutaneous useMultiple-dose Vial
    How do I prepare and give an injection with Enbrel multiple-dose vial? A multiple-dose vial contains 25 mg of Enbrel. Storage of Enbrel multiple-dose vial - Store Enbrel multiple-dose vial in ...
  • INSTRUCTIONS FOR USE
    Front Panel Text - Read these instructions before using an AutoTouch® reusable autoinjector for use with Enbrel Mini® (etanercept) single-dose prefilled cartridge. Side 1 Text - Your healthcare ...
  • INSTRUCTIONS FOR USE
    AutoTouch® reusable - autoinjector for use with - Enbrel Mini® (etanercept) single-dose prefilled cartridge - User Manual - Table of Contents - Getting Started4 - Reference ...
  • INSTRUCTIONS FOR USE
    AutoTouch Connect® reusable autoinjector - for use with - Enbrel Mini® (etanercept) single-dose prefilled cartridge - User Manual - Table of Contents - Getting Started4 - Reference ...
  • Instructions for Use Enbrel® (en-brel) (etanercept) injection, for subcutaneous use single-dose vial
    Read this Instructions for Use before you start taking Enbrel and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare ...
  • SPL UNCLASSIFIED SECTION
    REFERENCE GUIDE - Side 1Reference Guide - Enbrel® (en-brel) (etanercept) injection, for subcutaneous use - Single-Dose Prefilled SureClick® Autoinjector - 50 mg/mLRead all instructions in carton ...
  • PRINCIPAL DISPLAY PANEL - 25 mg/0.5 mL Syringe Carton
    Contains 4 Single-Dose Prefilled Syringes - NDC 58406-010-04 - Enbrel® etanercept - 25 - mg/0.5 mL - Not made with - natural rubber latex - 25 mg/0.5 mL - Single-Dose Prefilled Syringe - Attention: Not for use ...
  • PRINCIPAL DISPLAY PANEL - 50 mg/mL Syringe Carton
    Contains 4 Single-Dose Prefilled Syringes - NDC 58406-021-04 - Enbrel® etanercept - 50 - mg/mL - Not made with - natural rubber latex - 50 mg/mL - Single-Dose Prefilled Syringe - Attention: Not for use in ...
  • PRINCIPAL DISPLAY PANEL - 50 mg/mL Autoinjector Carton
    Contains 4 Single-Dose Prefilled Autoinjectors - NDC 58406-032-04 - Enbrel® etanercept - 50 - mg/mL - Not made with - natural rubber latex - SureClick® Autoinjector - 50 mg/mL - Single-Dose Prefilled ...
  • PRINCIPAL DISPLAY PANEL
    PRINCIPAL DISPLAY PANEL - Contains 4 Multi-Dose Trays - NDC 58406-425-34 - AMGEN® Enbrel® etanercept - 25 mg/vial - Multiple-Dose Vial - See package insert for full prescribing information - and ...
  • PRINCIPAL DISPLAY PANEL - 50 mg/mL Cartridge Carton
    Contains 4 Single-dose prefilled cartridges - NDC 58406-044-04 - Enbrel® etanercept - 50 - mg/mL - Not made with - natural rubber latex - Enbrel Mini® prefilled cartridge - 50 mg/mL - Single-dose prefilled ...
  • PRINCIPAL DISPLAY PANEL - 50 mg/mL Single-dose Prefilled Cartridge Autoinjector Label
    NDC 58406-480-01 - AMGEN® Bluetooth® AutoTouch Connect™ reusable autoinjector - For use with Enbrel Mini® (etanercept) single-dose prefilled cartridge - Contains 1 AutoTouch Connect™ reusable ...
  • PRINCIPAL DISPLAY PANEL - 25 mg/0.5 mL Vial Carton
    4 Single-Dose Vials, each vial is 25 mg/0.5mL - NDC 58406-055-04 - AMGEN® Enbrel® etanercept - Injection - 25 - mg - 25 mg/0.5 mL - Single-Dose Vial – Discard unused portion - For Subcutaneous Use Only ...
  • INGREDIENTS AND APPEARANCE
    Product Information